Information Provided By:
Fly News Breaks for June 5, 2017
EPZM
Jun 5, 2017 | 07:22 EDT
After Epizyme presented interim data from the epithelioid sarcoma and synovial sarcoma cohorts of its ongoing Phase II trial of tazemetostat, JMP Securities analyst Michael King says that the overall survival rate of those patients who have responded to treatments "provides an early but robust indication of tazemetostat's potential for providing clinical benefit in this patient population." He keeps a $28 price target and Outperform rating on the stock.
News For EPZM From the Last 2 Days
There are no results for your query EPZM